This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $74.56, marking a -0.01% move from the previous day.
GILD vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GILD vs. ILMN: Which Stock Is the Better Value Option?
The Final Chapter of Chesapeake Energy Story?
by Mark Vickery
Finding difficulties in dealing with its now $10 billion in debt, fracking pioneer Chesapeake Energy (CHK) has announced it is filing for Chapter 11 bankruptcy protection.
Chesapeake Energy Files Chapter 11
by Zacks Equity Research
Chesapeake Energy Files Chapter 11
Gilead's (GILD) Remdesivir Gets CHMP Approval Recommendation
by Zacks Equity Research
Gilead's (GILD) experimental coronavirus drug, remdesivir, has been recommended for approval by the EMA's human medicines committee.
3 Stocks to Buy as Companies Speed Up Vaccine Production
by Ritujay Ghosh
Although the FDA is yet to approve a drug or treatment for COVID-19, companies have already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.
Invest in the Future With Megatrend ETFs
by Neena Mishra
These ETFs invest in fast growing areas like robotics and AI, genomics and cybersecurity.
Alexion's (ALXN) SC Ultomiris Meets Primary Goal in Phase III
by Zacks Equity Research
Alexion's (ALXN) subcutaneous formulation of Ultomiris meets primary objective in a late-stage study.
Gilead to Buy 49.9% Stake in Private Biotech for $275M
by Zacks Equity Research
Gilead (GILD) to purchase 49.9% equity interest in privately-held Pionyr Immunotherapeutics. The company can later also exercise an option to acquire the rest of Pionyr.
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GILD) Outperforming Other Medical Stocks This Year?
Vertex (VRTX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $75.05 in the latest trading session, marking a -0.82% move from the prior day.
Gilead to Start Studies for an Inhaled Version of Remdesivir
by Zacks Equity Research
Gilead (GILD) announces plans to start studies for an inhaled version of the experimental candidate, remdesivir, in August.
Novartis Discontinues HCQ Study Due to Enrollment Challenges
by Zacks Equity Research
Novartis (NVS) abandons its HCQ study in COVID-19 patients due to enrollment challenges.
Regeneron Gets FDA Nod for Dupixent 300 Mg Pre-Filled Pen
by Zacks Equity Research
Regeneron (REGN) wins FDA approval for a 300-mg, single-dose, pre-filled pen for asthma drug, Dupixent.
Bet on These 5 High Earnings Yield Stocks to Book Profits
by Zacks Equity Research
Earnings yield has an edge over P/E ratio as it can be used to compare a stock with not just other stocks but also with fixed income securities.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $74.62, moving +0.88% from the previous trading session.
Oxford Discovers COVID-19 Treatment, Plus Record Retail Sales
by Mark Vickery
Dexamethasone is a generic anti-inflammatory drug already prescribed by physicians more than a million times per year, for various conditions.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge
FDA Ends Hydroxychloroquine's Emergency Use for Coronavirus
by Kinjel Shah
The FDA said that chloroquine and hydroxychloroquine are unlikely to prove effective in treating COVID-19 as the known benefits outweigh the risks.
3 Big Biotechs Poised for Growth Amid Coronavirus Pandemic
by Ekta Bagri
We highlight a few leading players from the biotech sector, who are likely to see a good run as the year progresses.
Lilly Begins Phase III Study on Olumiant for Coronavirus
by Zacks Equity Research
Lilly's (LLY) Olumiant is being studied for COVID-19 on the assumption that JAK1 and JAK2 inhibition may reduce cytokine storm, a complication associated with COVID-19.
Dr. Reddy's Inks Deal With Gilead Sciences for Remdesivir
by Zacks Equity Research
Dr. Reddy Laboratories (RDY) inks a deal with Gilead to register, manufacture and sell the latter's Remdesivir ??? a potential treatment for COVID-19 ??? in 127 countries including India.
Roche (RHHBY) Presents Positive Data on Venclexta at EHA 2020
by Zacks Equity Research
Roche (RHHBY) provides pipeline updates at the EHA Virtual Congress Press Briefing.
GILD vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
GILD vs. ILMN: Which Stock Is the Better Value Option?